Evidence map›Paper›PMID 41032085›Full record

ReviewZeitschrift fur Rheumatologie2025

[Management of osteologic and renal comorbidities in patients with rheumatic diseases].

A Schatz, P Xanthouli, K Triantafyllias, R Bergner

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

A SchatzRZ Rheumazentrum Rheinland-Pfalz, Bad Kreuznach, Deutschland.
P XanthouliZentrum für pulmonale Hypertonie, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
K TriantafylliasRZ Rheumazentrum Rheinland-Pfalz, Bad Kreuznach, Deutschland.
R BergnerMedizinische Klinik A - Nephrologie, Rheumatologie, Hämato-Onkologie, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Deutschland. bergnerr@klilu.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis as well as renal, pulmonary, and cardiovascular diseases must always be considered in the treatment of patients with inflammatory rheumatic diseases. Regardless of whether they are an organ manifestation of the underlying rheumatic disease, a medication side effect, or a comorbidity, these diseases have a decisive influence on morbidity, mortality, and therapeutic decisions. Osteoporosis and renal diseases require increased vigilance from the treating rheumatologist, as they are often initially asymptomatic. The following article provides guideline-based recommendations for monitoring and treating patients with inflammatory rheumatic diseases and comorbid osteoporotic or renal disease.

Indexed as

Antirheumatic AgentsKidney DiseasesNephrologyOsteoporosisPractice Guidelines as TopicRheumatic DiseasesRheumatologyComorbidityEvidence-Based MedicineGermanyHumansAntirheumatic AgentsAntiresorptive drugsGlucocorticoidsOsteoporosisRenal diagnosticsRenal insufficiency

Identifiers

PMID41032085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.